堪萨斯分枝杆菌临床分离株在2个月经验性抗分枝杆菌治疗前后的耐药谱分析
该研究回顾性分析上海2017至2019年191例堪萨斯分枝杆菌肺病患者,采用全基因组测序和肉汤微量稀释法测定最低抑菌浓度。结果显示基线分离株对乙胺丁醇(118/191,61.8%)和4 μg/mL异烟肼(32/191,16.8%)耐药率高,经验性治疗2个月后50.0%(23/46)患者出现利福平、乙胺丁醇和/或异烟肼最低抑菌浓度升高,强调启动治疗前明确菌种鉴定的紧迫性。
要点
- 191例中24.1%(46/191)在2个月抗分枝杆菌治疗后持续培养阳性。
- 基线分离株对乙胺丁醇耐药118/191(61.8%),对4 μg/mL异烟肼耐药32/191(16.8%)。
- 46例配对分离株中50.0%(23/46)出现利福平、乙胺丁醇和/或异烟肼最低抑菌浓度升高。
核心结论
- 上海 circulating 堪萨斯分枝杆菌临床株对乙胺丁醇和异烟肼存在高比例固有耐药。
- 经验性抗分枝杆菌治疗下耐药性增加,凸显启动治疗前明确菌种鉴定的紧迫性。
研究设计与样本
- 回顾性分析2017至2019年上海所有诊断为堪萨斯分枝杆菌肺病的患者。
- 采用全基因组测序和肉汤微量稀释法测定抗分枝杆菌药物的最低抑菌浓度。
主要发现
- 共191例患者诊断为堪萨斯分枝杆菌肺病,其中24.1%(46/191)在2个月抗分枝杆菌治疗后持续培养阳性。
- 全基因组测序显示46对配对分离株差异小于17个单核苷酸多态性,排除外源性再感染可能。
- 超过90%的基线分离株对利福平、克拉霉素、莫西沙星或阿米卡星敏感,而对乙胺丁醇耐药118/191(61.8%),对4 μg/mL异烟肼耐药32/191(16.8%)。
- 两株分离株对利福霉素类高度耐药(利福平最低抑菌浓度大于8 μg/mL,利福布汀最低抑菌浓度8 μg/mL),均携带rpoB突变(S454L)。
- 50.0%(23/46)的患者出现对利福平、乙胺丁醇和/或异烟肼的最低抑菌浓度升高。
临床怎么用
- 作者认为,经验性抗分枝杆菌治疗下耐药性增加,凸显启动治疗前明确菌种鉴定的紧迫性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mycobacterium kansasii pulmonary disease is frequently misdiagnosed and treated as tuberculosis, especially in countries with high tuberculosis burden. This study aimed to investigate the drug resistance profile of M.kansasii in patients with M.kansasii pulmonary disease in Shanghai and to determine the variations in drug resistance after 2 months of antimycobacterial treatment. METHODS: All patients with a diagnosis of M.kansasii pulmonary disease from 2017 to 2019 in Shanghai were retrospectively analysed. Whole-genome sequencing was performed, and the minimum inhibitory concentration (MIC) to antimycobacterial drugs was measured using the broth microdilution method. RESULTS: In total, 191 patients had a diagnosis of M.kansasii pulmonary disease. Of them, 24.1% (46/191) had persistent positive culture after 2 months of antimycobacterial treatment. Whole-genome sequencing revealed that the 46 paired isolates had a difference of <17 single nucleotide polymorphisms, thus excluding the possibility of exogenous reinfection. More than 90% of the baseline isolates were sensitive to rifampin, clarithromycin, moxifloxacin, or amikacin, whereas a high resistance to ethambutol (118/191, 61.8%) and 4 μg/mL of isoniazid (32/191, 16.8%) were observed. Two isolates presented high resistance to rifamycin (i.e. a rifampin MIC of >8 μg/mL and a rifabutin MIC of 8 μg/mL) both containing the rpoB mutation (S454L). The increase of MIC to rifampin, ethambutol, and/or isoniazid was identified in 50.0% (23/46) of the patients. DISCUSSION: A high prevalence of innate resistance to ethambutol and isoniazid was observed among circulating M.kansasii clinical strains in Shanghai. The increase in drug resistance under empirical antimycobacterial treatment highlighted the urgency of definitive species identification before initiating treatment.
引用
- Zhang Y, Yu C, Jiang Y, et al. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment. Clin Microbiol Infect. 2022. PMID: 36209990. doi:10.1016/j.cmi.2022.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。